Orchard Therapeutics Stock News

Orchard Therapeutics plc - ADR (ORTX) shares closed today 12.1% higher than it did at the end of yesterday. The stock is currently down 73.1% year-to-date, down 73.9% over the past 12 months, and down 91.7% over the past five years. Today, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 0.3%. Trading Activity Shares traded as high as $1.45 and as low as $1.16 this week.Shares closed 85.7% below its 52-week high and 12.1% above its 52-week low.Trading volume this week was 317.6% higher than the 10-day average and 627.1% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 83.1% The company's stock price performance over the past 12 months lags the peer average by 72.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Are these $3 penny stocks worth buying in 2022? The post Top Penny Stocks to Buy Under $3?

Analysts expect Orchard Therapeutics plc (NASDAQ:ORTX) to post ($0.28) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Orchard Therapeutics earnings, with estimates ranging from ($0.30) to ($0.25). Orchard Therapeutics reported earnings per share of ($0.34) during the same quarter last year, which would indicate []

During the last session, Orchard Therapeutics plc (NASDAQ:ORTX)’s traded shares were 1.25 million. At the end of the trading day, the stock’s price was $1.20, reflecting an intraday loss of -6.25% or -$0.08. The 52-week high for the ORTX share is $9.08, that puts it down -656.67 from that peak though still a striking 3.33% … Is Orchard Therapeutics plc (NASDAQ: ORTX) Hit More of the Losses Given A -656.67% Dip From High? Read More »

Wall Street brokerages predict that Orchard Therapeutics plc (NASDAQ:ORTX) will report earnings per share (EPS) of ($0.28) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Orchard Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.30) and the highest estimate coming in at ($0.25). Orchard Therapeutics posted […]

Orchard Therapeutics plc (NASDAQ:ORTX) was the recipient of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 1,860,000 shares, a drop of 67.0% from the November 15th total of 5,640,000 shares. Approximately 1.6% of the shares of the company are sold short. Based on […]

Wall Street analysts predict that Orchard Therapeutics plc (NASDAQ:ORTX) will post $1.00 million in sales for the current quarter, Zacks reports. Three analysts have issued estimates for Orchard Therapeutics earnings. The lowest sales estimate is $490,000.00 and the highest is $1.70 million. The company is scheduled to announce its next quarterly earnings results on Tuesday, []

Orchard Therapeutics plc - ADR (ORTX) shares closed today at 0.7% above its 52 week low of $1.35, giving the company a market cap of $176M. The stock is currently down 67.4% year-to-date, down 71.2% over the past 12 months, and down 89.9% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 53.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 247.5% The company's stock price performance over the past 12 months lags the peer average by 313.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

In the latest trading session, 1.34 million Orchard Therapeutics plc (NASDAQ:ORTX) shares changed hands as the companys beta touched 0. With the companys most recent per share price at $1.60 changed hands at -$0.17 or -9.73% at last look, the market valuation stands at $218.29M. ORTXs current price is a discount, trading about -467.5% off Orchard Therapeutics plc (NASDAQ: ORTX) Stock: More Upside Ahead? Read More »

BOSTON and LONDON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present and be availabl

Novel Discovery Research in HSC-generated Antigen-specific Regulatory T Cells Disclosed

Gene therapy experts Fulvio Mavilio, Ph.D., and Nicoletta Loggia, Ph.D., join as chief scientific officer and chief technical officer, respectively

BOSTON and LONDON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will webcast a virtual R&D Investor Event on T

BOSTON and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the Compensation Committee of Orchard's Board of Directors

With the trading day more than halfway over, the broad markets had made a comeback from the open but for the most part they were still negative.